Evidence map›Paper›PMID 25393640›Full record

Trial reportThe Journal of clinical endocrinology and metabolism2015

Liraglutide reduces oxidative stress and restores heme oxygenase-1 and ghrelin levels in patients with type 2 diabetes: a prospective pilot study.

Manfredi Rizzo, Nicola Abate, Manisha Chandalia, Ali A Rizvi, Rosaria V Giglio, Dragana Nikolic, Antonella Marino Gammazza, Ignazio Barbagallo, Esma R Isenovic, Maciej Banach and 2 more

Registry-linked trialOpen access · bronzeAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of clinical endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03377335 (Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes), which is not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03377335 phase4unknown statusstarted 2017, after this paper: background citation

Effect of Dapagliflozin on Cardio-Metabolic Risk Factors in Patients With Type-2 Diabetes

Ran2017Enrolled186Registered outcomes6Posted comparisons0ConditionsType 2 Diabetes MellitusArmsDapagliflozin 10mg, Metformin
PMID 26864445PMID 24559258PMID 27912784PMID 24349318PMID 22197629PMID 21595628PMID 26980776PMID 20525999PMID 26114349PMID 18418229PMID 26493719other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 110 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Use of flash glucose-sensing technology in patients with type 2 diabetes treated with liraglutide combined with CSII: a pilot study.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020
    Trial
  6. AltilixNutrients · 2019
    Trial
  7. Liraglutide relieves cardiac dilated function than DPP-4 inhibitors.European journal of clinical investigation · 2018
    Trial
  8. Trial
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Molecular Basis of Cardiomyopathies in Type 2 Diabetes.International journal of molecular sciences · 2024
    Review
  17. Review
  18. Article
  19. Incretin and glucagon receptor polypharmacology in chronic kidney disease.American journal of physiology. Endocrinology and metabolism · 2024
    Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 7 institutions in 4 countries.

Manfredi RizzoBiomedical Department of Internal Medicine and Medical Specialties (M.R., R.V.G., D.N., G.M.), University of Palermo, Palermo 90127, Italy; Euro-Mediterranean Institute of Science and Technology (M.R., A.M.G., I.B., G.L.V.), Palermo 90139, Italy; Division of Endocrinology, Diabetes and Metabolism (M.R., A.A.R.), University of South Carolina School of Medicine, Columbia, South Carolina 29203; Division of Endocrinology (N.A., M.C.), The University of Texas Medical Branch, Galveston, Texas 77555; Department of Experimental Biomedicine and Clinical Neurosciences (A.M.G.), University of Palermo, Palermo 90127, Italy; Department of Drug Sciences (I.B.), University of Catania, Catania 90125, Italy; Laboratory for Molecular Genetics and Radiobiology (E.R.I.), Vinca Institute, University of Belgrade, Belgrade 11000, Serbia; Department of Hypertension (M.B.), Medical University of Lodz, Lodz 90-549, Poland; and Department of Biomedical and Biotechnological Sciences (G.L.V.), University of Catania, Catania 90125, Italy.
Nicola Abate
Manisha Chandalia
Ali A Rizvi
Rosaria V Giglio
Dragana Nikolic
Antonella Marino Gammazza
Ignazio Barbagallo
Esma R Isenovic
Maciej Banach
Giuseppe Montalto
Giovanni Li Volti
Istituto Euro Mediterraneo di Scienza e Tecnologia · ITUniversity of Palermo · ITThe University of Texas Medical Branch at Galveston · USMedical University of Lodz · PLUniversity of Belgrade · RSUniversity of Catania · ITUniversity of South Carolina · US

Funding

NCATS NIH HHS UL1 TR000071NCATS NIH HHS UL1TR000071
6 · The paper itself

Abstract

contextLiraglutide is a glucagon-like peptide-1 analog and glucose-lowering agent whose effects on cardiovascular risk markers have not been fully elucidated.

objectiveWe evaluated the effect of liraglutide on markers of oxidative stress, heme oxygenase-1 (HO-1), and plasma ghrelin levels in patients with type-2 diabetes mellitus (T2DM). DESIGN AND

settingA prospective pilot study of 2 months' duration has been performed at the Unit of Diabetes and Cardiovascular Prevention at University of Palermo, Italy. Patients and Intervention(s): Twenty subjects with T2DM (10 men and 10 women; mean age: 57 ± 13 y) were treated with liraglutide sc (0.6 mg/d for 2 wk, followed by 1.2 mg/d) in addition to metformin (1500 mg/d orally) for 2 months. Patients with liver disorders or renal failure were excluded. MAIN OUTCOME MEASURE(S): Plasma ghrelin concentrations, oxidative stress markers, and heat-shock proteins, including HO-1 were assessed.

resultsThe addition of liraglutide resulted in a significant decrease in glycated hemoglobin (HbA1c) (8.5 ± 0.4 vs 7.5 ± 0.4%, P < .0001). In addition, plasma ghrelin and glutathione concentrations increased (8.2 ± 4.1 vs 13.6 ± 7.3 pg/ml, P = .0007 and 0.36 ± 0.06 vs 0.44 ± 0.07 nmol/ml, P = .0002, respectively), whereas serum lipid hydroperoxides and HO-1 decreased (0.11 ± 0.05 vs 0.04 ± 0.07 pg/ml, P = .0487 and 7.7 ± 7.7 vs 3.6 ± 1.8 pg/ml, P = .0445, respectively). These changes were not correlated with changes in fasting glycemia or HbA1c.

conclusionsIn a 2-months prospective pilot study, the addition of liraglutide to metformin resulted in improvement in oxidative stress as well as plasma ghrelin and HO-1 concentrations in patients with T2DM. These findings seemed to be independent of the known effects of liraglutide on glucose metabolism.

Indexed as

AdultAgedDiabetes Mellitus, Type 2Drug Therapy, CombinationFemaleGhrelinGlucagon-Like Peptide 1Heme Oxygenase-1HumansHypoglycemic AgentsLiraglutideMaleMetforminMiddle AgedOxidative StressPilot ProjectsGhrelinGlucagon-Like Peptide 1Heme Oxygenase-1Hypoglycemic AgentsLiraglutideMetformin

Identifiers

PMID25393640
PMCPMC4318909
OpenAlexW2132146653

What Socratic holds

Texttitle and abstract
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.